---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-26-000019"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2026-08-06T12:03:18+00:00"
generated_at: "2026-08-06T12:05:39.340714+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novavax Q2 2026 revenue $57M, net loss $53M; raises full-year revenue framework to $235-275M

## Summary
- Total revenue $57M (down 76% YoY); net loss $53M vs net income $107M in Q2 2025.
- Raised full-year 2026 Adjusted Total Revenue framework to $235-275M (from $230-270M).
- Sanofi partnership: Phase 3 CIC trial start triggers $125M milestone; tech transfer completion mid-2027 triggers $75M milestone.
- Cash $724M as of June 30, 2026, down from $751M at Dec 31, 2025.
- Combined R&D and SG&A expense guidance improved to $370-410M (from $380-420M).

## SEC filing metadata
- accession: 0001000694-26-000019
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2026-08-06T12:03:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/0001000694-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/nvax-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-26-000019
- JSON: https://secwatch.observer/filing/0001000694-26-000019.json
- Plain text: https://secwatch.observer/filing/0001000694-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.